Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.77 +0.14%

+$0.02 today

Market cap
$1.37B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 7.23M

Average 6.11M

NTLA Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Intellia Therapeutics, Inc.NASDAQ: NTLA

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns positive

Q1 FY2026 other non-cash items was $369K, compared with -$155K a year earlier. Trailing-twelve-month other non-cash items was $34M. Over 3 fiscal years it compounded at -6.1% a year.

Context

  • Other non-cash items amounted to 117.2% of revenue in FY2025, up 106.4 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other non-cash items holds near $369K or moves back toward the trailing-twelve-month quarterly average of $8.5M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$369K-99.1% QoQ
Last fiscal yearDec 2025
$79.34M+1360.3% YoY
LTMMar 2026
$34M+147.5% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+338.1%——
1 year+1360.3%——
3-year CAGR-6.1%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
79.34M USD
Year-over-year change
+1360.3%
4-year CAGR
+128.0%

Other Non-Cash Items vs competitors

How NTLA compares with its peers on the latest reported figures

  • NTLA's LTM Mar 2026 other non-cash items of $34M is the 5th largest of the 10 companies compared; the peer median is $5.85M.
  • Its year-over-year change of +147.5% is the 6th highest of 10, against a peer median of +152.1%.
  • Other non-cash items amounts to 51.4% of revenue for NTLA, versus a peer median of 116.4%.
NTLA Competitors Peer median
Other Non-Cash Items for NTLA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$179.4M +22894.9%-19.7%224.9%
BEAMBeam Therapeutics Inc.LTM Jun 2026$144.7M +1256.1%+86.8%92.7%
PGENPrecigen, Inc.LTM Jun 2026$100.82M +152.1%—117.6%
SANASana Biotechnology, Inc.LTM Mar 2026$91.96M +300.7%——
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$34M +147.5%-6.1%51.4%
CRSPCRISPR Therapeutics AGLTM Sep 2026$29.31M -144.5%+80.0%116.4%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$24.36M +579.5%+34.3%217.5%
EDITEditas Medicine, Inc.LTM Mar 2026$5.85M +61.3%—15.1%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$5.66M +90.8%——
QUREuniQure N.V.LTM Mar 2026$4.32M +16.7%-27.2%23.9%
Peer median (excluding NTLA) $5.85M+152.1%+34.3%116.4%

Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(267.89M)(474.19M)(481.19M)(519.02M)(519.02M)
Depreciation & Amortization6.89M7.57M8.98M10.29M10.29M
Deferred Income Tax8.93M0000
Stock-Based Compensation47.01M91.4M134.05M154.27M154.27M
Change in Working Capital(22.9M)(53.87M)(52.45M)11.88M(73.75M)
Accounts Receivables99K(1.74M)(32.69M)27.94M(951K)
Inventory7.82M0000
Accounts Payables529K(4.58M)2.52M6.8M5.99M
Other Working Capital(31.36M)(47.55M)(22.29M)(22.86M)(78.79M)
Other Non-Cash Items2.94M95.8M(3.47M)(6.3M)79.34M
Operating Cash Flow(225.03M)(333.29M)(394.09M)(348.88M)(348.88M)
Capital Expenditures(12.76M)(58.39M)(13.99M)(5.78M)(5.78M)
Acquisitions (Net)(3M)(44.68M)000
Purchases of Investments(1.02B)(429.03M)(904.46M)(935.57M)(935.57M)
Sales of Investments485.6M647.58M887.1M1.07B1.05B
Other Investing Activities044.83M0020.97M
Investing Cash Flow(550.78M)160.31M(31.35M)125.57M125.57M
Debt Repayment00000
Common Stock Issued693.57M565.79M119.8M176.9M131.49M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities43.12M17.17M10.53M8.85M54.26M
Financing Cash Flow736.69M582.96M130.32M185.75M185.75M
Effect of Forex Changes00000
Net Change in Cash(39.12M)409.98M(295.11M)(37.57M)(37.57M)
Free Cash Flow(237.79M)(391.68M)(408.07M)(354.66M)(354.66M)

Intellia Therapeutics, Inc.

NASDAQ:NTLA

Intrinsic Alpha fair value

Locked

Current Price

$9.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.